You are here

Article info

Article menu

Download PDFPDF

XML
Review
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach

Authors

  • Judith M Versluis Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Daniela S Thommen Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Christian U Blank Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Christian U Blank; c.blank{at}nki.nl
View Full Text

Citation

Versluis JM, Thommen DS, Blank CU
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach
Journal for ImmunoTherapy of Cancer 2020;8:e001352. doi: 10.1136/jitc-2020-001352

Publication history

  • Accepted July 21, 2020
  • First published August 24, 2020.
Online issue publication 
August 24, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.